Skip to search formSkip to main contentSkip to account menu

crisnatol mesylate

An anticancer drug that interferes with the DNA in cancer cells.
National Institutes of Health

Related topics

Related topics

1 relation
crisnatol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
This Phase I and pharmacological study was performed to assess the feasibility of administering the polycyclic aromatic… 
1997
1997
Long-term response to crisnatol mesylate in patients with glioma.
A total of 26 patients (6 with anaplastic astrocytoma; 20 with glioblastoma) were treated with crisnatol mesylate. All patients… 
1992
1992
A phase II study of crisnatol mesylate in patients with ovarian carcinoma
SummaryFourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate… 
1992
1992
Microbial Production of a Crisnatol Metabolite
Microbial metabolism studies of crisnatol (1), a new DNA interca-lator, has resulted in the isolation and characterization of a… 
1991
1991
Crisnatol mesylate: Phase I dose escalation by extending infusion duration
SummaryCrisnatol mesylate is a rationally designed cytotoxic arylmethylamino-propanediol with broad spectrum cytotoxic activity… 
1990
1990
Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo.
The pharmacodynamics of a new series of antitumor DNA intercalators, known as arylmethylaminopropanediols (AMAPs), has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)